Efficacy and safety of anakinra in adults presenting deteriorating respiratory symptoms from COVID-19: A randomized controlled trial

Bibliographic Details
Title:	Efficacy and safety of anakinra in adults presenting deteriorating respiratory symptoms from COVID-19: A randomized controlled trial
Authors:	Alexandra Audemard-Verger, Amélie Le Gouge, Vincent Pestre, Johan Courjon, Vincent Langlois, Marc-Olivier Vareil, Mathilde Devaux, Boris Bienvenu, Vincent Leroy, Radjiv Goulabchand, Léa Colombain, Adrien Bigot, Thomas Guimard, Youcef Douadi, Geoffrey Urbanski, Jean François Faucher, Laurence Maulin, Bertrand Lioger, Jean-Philippe Talarmin, Matthieu Groh, Joseph Emmerich, Sophie Deriaz, Nicole Ferreira-Maldent, Ann-Rose Cook, Céline Lengellé, Hélène Bourgoin, Arsène Mekinian, Achille Aouba, François Maillot, Agnès Caille
Source:	PLoS ONE, Vol 17, Iss 8 (2022)
Publisher Information:	Public Library of Science (PLoS), 2022.
Publication Year:	2022
Collection:	LCC:Medicine LCC:Science
Subject Terms:	Medicine, Science
More Details:	Objective We aimed to investigate whether anakinra, an interleukin-1receptor inhibitor, could improve outcome in moderate COVID-19 patients. Methods In this controlled, open-label trial, we enrolled adults with COVID-19 requiring oxygen. We randomly assigned patients to receive intravenous anakinra plus optimized standard of care (oSOC) vs. oSOC alone. The primary outcome was treatment success at day 14 defined as patient alive and not requiring mechanical ventilation or extracorporeal membrane oxygenation. Results Between 27th April and 6th October 2020, we enrolled 71 patients (240 patients planned to been enrolled): 37 were assigned to the anakinra group and 34 to oSOC group. The study ended prematurely by recommendation of the data and safety monitoring board due to safety concerns. On day 14, the proportion of treatment success was significantly lower in the anakinra group 70% (n = 26) vs. 91% (n = 31) in the oSOC group: risk difference—21 percentage points (95% CI, -39 to -2), odds ratio 0.23 (95% CI, 0.06 to 0.91), p = 0.027. After a 28-day follow-up, 9 patients in the anakinra group and 3 in the oSOC group had died. Overall survival at day 28 was 75% (95% CI, 62% to 91%) in the anakinra group versus 91% (95% CI, 82% to 100%) (p = 0.06) in the oSOC group. Serious adverse events occurred in 19 (51%) patients in the anakinra group and 18 (53%) in the oSOC group (p = 0·89). Conclusion This trial did not show efficacy of anakinra in patients with COVID-19. Furthermore, contrary to our hypothesis, we found that anakinra was inferior to oSOC in patients with moderate COVID-19 pneumonia.
Document Type:	article
File Description:	electronic resource
Language:	English
ISSN:	1932-6203
Relation:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9351999/?tool=EBI; https://doaj.org/toc/1932-6203
Access URL:	https://doaj.org/article/a654617adbad4e2e95fef1473f11dac2
Accession Number:	edsdoj.654617adbad4e2e95fef1473f11dac2
Database:	Directory of Open Access Journals
Full text is not displayed to guests.	Login for full access.

More Details
ISSN:	19326203
Published in:	PLoS ONE
Language:	English